As of this week, Montana has officially launched an experimental drug approval pathway that bypasses the federal Food and Drug Administration, positioning itself as a regulatory outlier in the American biotech landscape. Biotech companies can now submit applications to a state-created review board for $12,500 per drug submission, seeking approval to market experimental treatments that have passed only preliminary testing phases—sometimes involving as few as 10 healthy volunteers. This represents a dramatic expansion beyond Montana's existing right-to-try law, which all 50 states technically possess but rarely activate. The new pathway creates what amounts to an alternative approval infrastructure, fundamentally shifting regulatory authority from federal to state hands. The timing aligns with growing patient desperation: families like that of Brody DeVault, a two-year-old diagnosed with a rare developmental disorder, face years-long waits for FDA approval of potentially life-altering treatments while their children's conditions progress.
The review board's operational structure remains partially opaque, though state officials have indicated it will consist of medical professionals tasked with evaluating safety and efficacy claims within compressed timeframes. The $12,500 application fee is charged per drug submission, potentially creating recurring revenue for Montana's health department. However, crucial details about the board's composition, appeal processes, funding mechanisms beyond application fees, and liability frameworks remain undefined in publicly available documents. This regulatory gap has alarmed medical ethicists and patient safety advocates. Dr. Arthur Caplan, a prominent bioethicist at NYU Grossman School of Medicine, has warned that Montana's model creates precisely the conditions under which vulnerable, desperate families become targets for unproven treatments with no robust safety guardrails. The FDA has not publicly responded to Montana's move, though the agency maintains authority over interstate commerce, potentially creating jurisdictional conflicts.
What distinguishes Montana's approach from standard right-to-try laws is its preemptive approval pathway for sales to any patient, rather than requiring individual case-by-case FDA compassionate use requests. State officials argue this creates faster access for conditions lacking alternative treatments, though biotech companies have not yet disclosed applications or approvals under the new system. The model faces an inevitable test: if a patient harmed by an inadequately-tested drug sues Montana or the approving company, courts will determine whether state regulatory authority supersedes federal drug safety standards. This jurisdictional conflict could reshape biotech regulation nationwide, particularly if other economically struggling states adopt similar frameworks to attract biotech investment. The stakes extend beyond Montana—the decision signals whether desperate patients' rights to experimental access will increasingly bypass scientific evidence standards, or whether federal oversight will reassert dominance over pharmaceutical safety.